CN111481528A - Medicine carrier and medicine composition based on acupoint transdermal administration, and preparation method and application thereof - Google Patents
Medicine carrier and medicine composition based on acupoint transdermal administration, and preparation method and application thereof Download PDFInfo
- Publication number
- CN111481528A CN111481528A CN202010210373.7A CN202010210373A CN111481528A CN 111481528 A CN111481528 A CN 111481528A CN 202010210373 A CN202010210373 A CN 202010210373A CN 111481528 A CN111481528 A CN 111481528A
- Authority
- CN
- China
- Prior art keywords
- carrier
- drug
- preparation
- pharmaceutical composition
- acupoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
A drug carrier and a drug composition based on acupoint transdermal drug delivery, a preparation method and an application thereof relate to the field of new dosage forms and new technology of drugs. The invention provides a preparation method of a drug carrier based on acupoint transdermal drug delivery, which is characterized by comprising the following steps: mixing at least one carrier matrix with at least one amphiphilic material and at least one benefit agent to form a homogeneous liquid; the invention also provides a medicine carrier prepared by the preparation method of the medicine carrier based on acupoint transdermal administration. The invention also provides a preparation method of the pharmaceutical composition based on acupoint transdermal administration, which is characterized by comprising the following steps: a step of fusion of the drug and the drug carrier as described above; the invention also provides a pharmaceutical composition prepared by the preparation method of the pharmaceutical composition. The pharmaceutical composition provided by the invention is a liquid melt with uniform, fine and temperature-sensitive characteristics, and the application range and the application method of the transdermal administration application based on acupuncture points.
Description
Technical Field
The invention relates to the field of new dosage forms and new technologies of medicines, in particular to a medicine carrier based on acupoint transdermal administration and a preparation method thereof, and a medicine composition based on the medicine carrier and a preparation method and application thereof.
Background
The acupoint transdermal drug delivery is a drug delivery method for treating internal diseases by external therapy expressed according to modern medical language, and is called as acupoint application expressed according to the traditional Chinese medicine. The acupoint pasting therapy is one of the methods of 'treating internal diseases externally' in the traditional Chinese medicine, and is the specific practice of 'treating internal diseases externally' theory in the traditional Chinese medicine.
The acupoint application therapy is originally seen in the 'prescription for fifty two diseases', the theoretical basis of the acupoint application therapy is established on the basis of the holistic concept of the traditional Chinese medicine and the theory of Chinese medicine channels and collaterals, and in long medical practice, according to the principle of treatment based on syndrome differentiation of the traditional Chinese medicine, the traditional Chinese medicine is applied to specific acupoints or affected parts (Ashi) of the skin after the formula is formed, and the aims of conditioning yin and yang of viscera and dredging meridians and qi and blood are achieved through the stimulation of the acupoints and the action of medicines so as to prevent and treat diseases. The preparation method comprises grinding the Chinese medicinal materials into fine powder, and concocting with vinegar, wine, succus Zingiberis recens or Mel at a certain ratio to obtain pill, powder, ointment, paste, etc., or applying on acupuncture point with aromatic Chinese medicinal materials. The stimulation of the herbs can stimulate meridians and qi, and communicate with the upper and lower parts of the body through meridians and collaterals, so as to nourish the whole body by circulating qi and blood. The theory of the property of Chinese herbs holds that the Chinese herbs have different or similar specific properties, namely: the four flavors, five flavors, ascending, descending, sinking and floating, and entering meridians were recorded in Shen nong's herbal Jing and Jie Lu (records of Shen nong's herbal Jing and Jie). The acupoint application therapy utilizes different attributes of the medicines and adopts dialectical medicines to exert specific effects. Therefore, the meridians play an important role in the occurrence, development and transmission of diseases, and the acupoints are the locations where qi of the zang-organs in the entire meridian system accumulates and enters and exits the body surface.
Research and arrangement of relevant documents in the last forty years shows that the traditional Chinese medicine acupoint application therapy is developed to date, is widely applied to treatment of various clinical diseases, and achieves obvious curative effects, wherein the diseases relate to internal, external, gynecological, infantile, five sense organs and other departments, and the covered diseases include lung diseases, such as: chronic bronchitis, asthma, cough, expectoration, short breath, dyspnea, etc., and coronary heart disease, angina pectoris, facial paralysis, dysmenorrhea, gout, etc. However, the current research focuses on the evaluation and experience summary of clinical efficacy, and few researches on factors influencing the efficacy are made, wherein the acupoint application dosage form is one of the main reasons influencing the efficacy. At present, the traditional ancient dosage forms such as pills, powder, paste and paste are still used, although some newer dosage forms such as ointment, plaster, rubber paste, film coating agent and emplastrum are also appeared in succession for decades, the dosage forms are not completely suitable for the application of acupoint transdermal administration, and in essence, the dosage forms belong to backward preparations, and high-level novel preparations suitable for the application of acupoint transdermal administration are not appeared, so that the development of the preparation level is not substantially progressed for decades. Currently, the lagging of the preparation level can not meet the requirements of clinical treatment and scientific research practice, and the development progress and clinical popularization and application of the application therapy are limited.
It should be noted that the theory of traditional Chinese medicine is developed and developed in a large number of clinical practices, which are essential sources of the development and development of the basic theory of traditional Chinese medicine. Physicians of different generations continuously sublime practical experience into theory through reading, clinical evidence and comprehension, and guide new practice by using new theory, and generate new theory in practice, thereby forming the traditional Chinese medicine theory system. The lagging clinical practice means hinders the innovative development of the traditional Chinese medicine theory, which is an important reason that the traditional Chinese medicine theory has not substantially developed since the modern times. Therefore, there is currently a contradiction between the late and late clinical practice of the theoretical development of traditional Chinese medicine. The inheritance and innovative development of traditional Chinese medicine should be based on practical viewpoints, and research ideas and methods are determined according to the basic principles and thinking ways of the traditional Chinese medicine theory and the practical application of the traditional Chinese medicine methodology under the framework of the traditional Chinese medicine theory system.
In view of the above, it is considered that the development of a novel preparation which is safe, efficient, convenient and controllable and embodies the characteristics of the traditional Chinese medicine is a necessary condition for expanding the clinical practice means, meeting the internal requirements of clinical disease prevention and treatment and clinical scientific research and further promoting the development of the theory of traditional Chinese medicine; in the research of a new preparation technology suitable for acupoint transdermal drug delivery, the establishment of a novel drug-loading platform is the key for improving the preparation level, developing a novel acupoint transdermal drug delivery preparation and realizing industrial development.
Disclosure of Invention
Under the framework of the theory system of traditional Chinese medicine, the basic principle and thinking mode of the theory of traditional Chinese medicine and the methodology of traditional Chinese medicine are applied, and the modern multidisciplinary new technology and new method are correctly known, combined and applied, which is the guiding idea followed by the invention. Based on the guiding thought, the invention aims to provide a novel drug-loading platform, namely a novel drug-loading platform which is based on the application of acupoint transdermal drug delivery of traditional Chinese medicine, has temperature sensitivity characteristics and uniform and fine characteristics, and is called as a liquid melt.
In order to achieve the above object, the present invention provides a method for preparing a pharmaceutical carrier for acupoint-based transdermal drug delivery, comprising the steps of: at least one carrier matrix selected from coco butter ester, litsea cubeba oil ester, palmitate ester, cocoa butter ester, coumarate ester and polyethylene glycol 200, at least one amphiphilic substance selected from sorbitan fatty acid ester, monooleate fatty acid ester, dioleate fatty acid ester, distearate fatty acid ester, polyglycerol ester-2-oleate and isostearic acid glyceride, and at least one beneficial additive selected from laurocapram, glycyrrhizic acid and its salts, glycyrrhetinic acid ester, glycerol, propylene glycol and plant aromatic oil, and mixing under appropriate conditions to form a homogeneous liquid; the ratio of the amphiphilic substance to the beneficial agent is 1-10: 1-10 parts by weight per 100 parts by weight of the carrier matrix; suitable conditions for forming a homogeneous liquid include: mixing at 40-90 deg.C for 5-60 min; the homogeneous liquid is the drug carrier.
The invention also provides a medicine carrier prepared by the preparation method of the medicine carrier based on acupoint transdermal administration.
The invention also provides a preparation method of the pharmaceutical composition based on acupoint transdermal administration, which is characterized by comprising the following steps: fusing the drug with the drug carrier as described above to form a homogeneous liquid melt; the loading amount of the drug carrier is 0.1-0.4 weight part per weight part of the drug carrier; the medicine comprises: single Chinese medicine extract, compound Chinese medicine extract, plant aromatic oil, or the combination of the two; the medicine can be extracted by the following extraction methods: extracting with water or ethanol (or mixed solvent of water and ethanol) at room temperature or under heating and refluxing, or with the aid of ultrasonic wave or microwave, or purifying with macroporous adsorbent resin, or extracting with supercritical extraction technology.
The invention also provides a pharmaceutical composition prepared by the preparation method of the pharmaceutical composition based on acupoint transdermal administration.
The medicinal composition obtained by the preparation method of the medicinal carrier and the medicinal composition based on acupoint transdermal administration, which are provided by the invention, has temperature sensitivity characteristic, namely the property of interconversion between solid and liquid at a temperature point between 34 and 37 ℃, and has uniform and fine characteristics when being in a liquid state, so that the medicinal composition is called as a liquid melt.
The invention provides a medicine carrier based on acupoint transdermal administration and a medicine composition obtained by a preparation method of the medicine carrier based on acupoint transdermal administration, which are based on the application range and the application method of acupoint transdermal administration.
Additional features and advantages of the invention will be set forth in the detailed description which follows, and in part will be obvious from the description.
Drawings
FIG. 1 is a process flow diagram of the present invention;
FIG. 2 is a chart comparing the melting points of the pharmaceutical compositions obtained in examples 1 to 4;
FIG. 3 is a graph showing the melting time limit comparison of the pharmaceutical compositions obtained in examples 1 to 4.
Detailed Description
The following detailed description of the embodiments of the present invention is provided in conjunction with the accompanying drawings, and it should be noted that the description of the embodiments herein is only for the purpose of illustration and explanation, and not for the purpose of limitation.
In the present invention, the term "liquid" is used broadly to refer to a liquid mixture in a homogeneous state without being otherwise specified.
In the present invention, the "mixing" or "contacting" may be carried out under stirring conditions without any reverse explanation, and the stirring speed may be conventionally selected.
The invention provides a preparation method of a drug carrier based on acupoint transdermal drug delivery, which is characterized by comprising the following steps: at least one carrier matrix selected from coco butter ester, litsea cubeba oil ester, palmitate ester, cocoa butter ester, coumarate ester and polyethylene glycol 200, at least one amphiphilic substance selected from sorbitan fatty acid ester, monooleate fatty acid ester, dioleate fatty acid ester, distearate fatty acid ester, polyglycerol ester-2-oleate and isostearic acid glyceride, and at least one beneficial additive selected from laurocapram, glycyrrhizic acid and its salts, glycyrrhetinic acid ester, glycerol, propylene glycol and plant aromatic oil, and mixing under appropriate conditions to form a homogeneous liquid; the ratio of the amphiphilic substance to the beneficial agent is 1-10: 1-10 parts by weight per 100 parts by weight of the carrier matrix; suitable conditions for forming a homogeneous liquid include: mixing at 40-90 deg.C for 5-60 min; the homogeneous liquid is the drug carrier.
According to the preparation method of the drug carrier based on acupoint transdermal administration provided by the invention, preferably, the carrier matrix can be at least one selected from coco oil ester, litsea cubeba oil ester, palmitate and cacao ester; among them, preferably, the amphiphilic substance may be at least one selected from the group consisting of sorbitan fatty acid ester, distearic acid fatty acid ester, polyglyceryl ester-2-oleate, and glyceryl isostearate; wherein, the beneficial additive can be at least one selected from laurocapram, glycyrrhizic acid and its salt, glycyrrhetinic acid and its salt, glycerol, propylene glycol, and plant aromatic oil.
According to the preparation method of the drug carrier based on acupoint transdermal administration provided by the invention, the carrier matrix, the amphiphilic substance and the beneficial additive are mixed under appropriate conditions to form a uniform liquid.
Wherein the suitable conditions are: mixing the amphiphilic substance and the beneficial agent in sequence with the carrier matrix in a molten state at a temperature of 40-90 ℃ under stirring.
The stirring conditions, the stirring speed thereof, may be conventional ones, such as: 100-2000 rpm, and the stirring time is 5-60 minutes, wherein, under the preferable conditions, the stirring time is 5-30 minutes.
According to the preparation method of the drug carrier based on acupoint transdermal administration provided by the invention, the amphiphilic substance and the beneficial additive account for 1-10: 1-10 parts by weight, preferably 2-7: 2-7 parts by weight per 100 parts by weight of the carrier matrix.
The invention also provides a medicine carrier prepared by the preparation method of the medicine carrier based on acupoint transdermal administration.
The invention also provides a preparation method of the pharmaceutical composition based on acupoint transdermal administration, which is characterized by comprising the following steps: fusing the drug with the drug carrier as described above to form a homogeneous liquid melt; the loading amount of the drug carrier is 0.1-0.4 weight part per weight part of the drug carrier; the medicine comprises: single Chinese medicine extract, compound Chinese medicine extract, plant aromatic oil, or the combination of the two; the medicine can be extracted by the following extraction methods: extracting with water or ethanol (or mixed solvent of water and ethanol) at room temperature or under heating and refluxing, or with the aid of ultrasonic wave or microwave, or purifying with macroporous adsorbent resin, or extracting with supercritical extraction technology.
Wherein, the step of fusing the drug and the drug carrier as described above, specifically, the drug and the drug carrier are contacted and mixed under the stirring condition of 100-; wherein, the rotation speed is 2000-.
Wherein, the stirring condition also comprises that the stirring time can be 5 to 60 minutes, and preferably 10 to 40 minutes.
Wherein the loading amount of the drug is 0.1-0.4 part by weight per part by weight of the drug carrier.
According to the method for preparing the pharmaceutical composition for acupoint-based transdermal administration provided by the invention, the liquid melt is judged based on the state characteristics of the uniform and fine molten state.
The preparation method of the pharmaceutical composition based on acupoint transdermal drug delivery provided by the invention relates to the traditional Chinese medicine extract and the extraction method, wherein the extraction means the reaggregation of the physical properties and the chemical properties of the traditional Chinese medicine; it should be noted that the property of Chinese herbs refers to the property of Chinese herbs having four flavors and five flavors, ascending, descending, sinking, floating and meridian tropism, and the property of Chinese herbs is a complex of physical and chemical properties inherent in Chinese herbs, and the performance of Chinese herbs is the result of the combined action of physical and chemical properties.
It should be noted that, the physical and chemical properties of the Chinese herbs, and the supporting body thereof is mainly the natural wood and/or fiber structure of the Chinese herbs, so the Chinese herb extracts involved in the herbs can be understood as the aggregate of the Chinese herbs which have lost the physical and chemical properties of the natural supporting body.
In view of the above, it should be noted that when the drug and the drug carrier are contacted, the drug and the drug carrier are fused together to form a liquid melt through the fusion step, which is understood to be that the carrier is newly provided to exert its inherent potency; in a word, after the traditional Chinese medicine is crushed into powder, the inherent wood structure and/or fiber structure still exist, so that the medicine property is confined and the traditional Chinese medicine is difficult to exert; when the carrier is newly given to form a liquid melt, the performance can be improved by adopting a specific method. It is therefore considered that this is of significance for the formation of a liquid melt.
In view of the above, the following needs are further explained: the performance of the method can be improved by adopting a specific method as described above, and the method can be realized by the following two aspects: firstly, based on the acupoint transdermal administration route, the medicine contacts with the acupoints and a certain range of skin around the acupoints, the transdermal absorption of the medicine is one of the routes for generating the medicine effect, the transdermal absorbent is one of the effective methods for enhancing the transdermal absorption, and the selected transdermal absorbent can be: laurocapram, dimethyl sulfoxide, etc., and the auxiliary transdermal absorbent can be: at least one or two and/or more of ethanol, propylene glycol, glycerol, plant aromatic oil, radix Angelicae sinensis oil, rhizoma Ligustici Chuanxiong oil, Carthami flos oil, etc.; preferably laurocapram and propylene glycol, and optionally vegetable aromatic oil; the ratio of laurocapram to propylene glycol is 1-3: 1-3 per 100 parts by weight of the pharmaceutical composition. This is based on the thought of chemical properties of Chinese herbs. Secondly, based on the acupoint transdermal administration route, the stimulation effect of the medicine on the acupoints and the conduction function of the channels and collaterals, and the thinking of the effect of 'sensing transmission along the channels' is considered. According to the principle of treatment based on syndrome differentiation of traditional Chinese medicine and the nature, taste and meridian tropism of traditional Chinese medicines, the compatibility of the traditional Chinese medicines with the nature of aromatic channeling is considered in the formula of the traditional Chinese medicines, and it is pointed out that aromatic substances contained in the traditional Chinese medicines are important components forming the property of the traditional Chinese medicines. In view of the above, the extraction needs to be completely retained in practice, but in view of the loss caused by extraction technology, the aromatic oil of the corresponding Chinese medicine can be used for supplement, so as to ensure the completeness of the Chinese medicine property. This is based on the thought of physical properties of Chinese herbs.
Therefore, according to the preparation method of the pharmaceutical composition based on acupoint transdermal administration provided by the invention, the plant aromatic oil involved in the medicine refers to the aromatic oil of the corresponding traditional Chinese medicine in the formula;
therefore, it is also possible to use the above-mentioned preparation method of the pharmaceutical carrier for transdermal drug delivery via acupuncture points, wherein the aromatic oil is involved in the beneficial additive, i.e. the aromatic oil of the corresponding Chinese medicinal herbs in the formulation.
In addition, it should be noted that antioxidants (e.g., tocopherol, ascorbic acid) and preservatives (e.g., paraben, chlorobutanol) can be used in the actual manufacture of the pharmaceutical composition as described above, and the method of use can be a conventional method and is not particularly limited.
The preparation method of the pharmaceutical composition based on acupoint transdermal administration provided by the invention comprises the following steps: single Chinese medicine extract, compound Chinese medicine extract and plant aromatic oil, or their mixture.
It should be noted that, the composition of the prescription of the Chinese medicine is not particularly limited, for example, according to the principle of treatment based on syndrome differentiation of Chinese medicine, different Chinese medicine prescriptions can be adopted for different purposes of prevention and treatment. The clinical transdermal administration via acupuncture points has proved to be effective in treating the following diseases, including: acute and chronic bronchitis, asthma, cough, expectoration, short breath and dyspnea of lung system diseases; coronary heart disease, angina pectoris, hypertension, etc. of the cardiovascular system; there are also: dysmenorrhea, prostatitis, infantile enuresis, cough, fever, etc.; also, not all disease species listed herein; moreover, there are likely to be more disease species that will prove effective when treated by acupoint transdermal administration; moreover, such clinical studies have been in progress.
The invention also provides a pharmaceutical composition prepared by the preparation method of the pharmaceutical composition based on acupoint transdermal administration. It should be noted that the pharmaceutical composition can be prepared to the required specifications according to the required physical dimensions and weight by using a production device with an autonomous design assembly, such as: the diameter is 20mm and the weight of the tablet is 1.0 g; or a disk shape with the diameter of 10mm and the weight of the disk is 0.5 g; the patch can also be in other shapes and heavy sheet, and can be made into acupoint patch with acupoint fixing material.
While the present invention has been described in detail with reference to the specific embodiments and preferred embodiments and further illustrated and explained with reference to the specific features and advantages thereof, it is to be understood that the present invention is not limited to the details of the foregoing embodiments, and that various combinations and modifications thereof may be made within the spirit, scope, and technical concept of the present invention, and the scope of the present invention is to be accorded the full scope of the claims.
In addition, it should be noted that, in the case where the respective specific technical features described in the above embodiments are combined in any appropriate manner without contradiction, various possible combinations of the present invention are not separately described in order to avoid unnecessary repetition.
It should also be noted that any reasonable combination of the various embodiments of the present invention and the following examples can be made without departing from the overall concept of the present invention, and should be considered as the disclosure of the present invention.
The present invention is further described in detail by the following examples, wherein the related compound traditional Chinese medicine extract needs to be described as follows: the compound traditional Chinese medicine extracts No. 1, No. 2, No. 3 and No. 4 are all self-made; the prescription composition and the extraction method are as follows: (not shown); the used Chinese medicinal materials are purchased from the market. Further, other raw materials or reagents used were all commercially available.
Example 1
Heating 1000g of pungent litse fruit oil at 70 ℃ for melting, sequentially adding 18g of polyglycerol ester-2-oleate, 12g of isostearic acid glyceride, 9g of sorbitan fatty acid ester, 4g of glycyrrhetinic acid, 16g of laurocapram and 8g of propylene glycol under continuous stirring at 200 revolutions per minute, and continuously stirring for 20 minutes to obtain a medicine carrier; then adding 250g of compound traditional Chinese medicine extract No. 1, stirring uniformly, and continuing for 20 minutes at 3500 r/min 50 ℃ by using a high-speed disperser to obtain 1317g of the pharmaceutical composition.
The pharmaceutical composition is prepared into solid round tablets with the diameter of 20mm and the weight of 1.0g by using a production device which is independently designed and assembled, and 1257 tablets are prepared.
Example 2
Heating 800g of litsea cubeba oil ester and 200g of cocoa bean ester to melt at 65 ℃, sequentially adding 24g of polyglycerol ester-2-oleate, 16g of isostearic acid glyceride, 12g of sorbitan fatty acid ester, 4g of glycyrrhetinic acid, 16g of laurocapram and 8g of propylene glycol under continuous stirring at 150 revolutions per minute, and continuously stirring for 20 minutes to obtain a medicine carrier; then adding 300g of compound traditional Chinese medicine extract No. 2, stirring uniformly, and continuing for 30 minutes at 3000 r/min 60 ℃ by using a high-speed disperser to obtain 1380g of the pharmaceutical composition.
The pharmaceutical composition is prepared into solid round tablets with diameter of 20mm and tablet weight of 1.2g by using a production device which is designed and assembled independently, and 1070 tablets are prepared.
Example 3
Heating 850g of litsea cubeba oil ester, 100g of palmitate and 50g of cocoa butter to melt at 75 ℃, sequentially adding 15g of sorbitan fatty acid ester, 25g of glyceryl distearate, 20g of glyceryl isostearate, 8g of dipotassium glycyrrhizinate, 16g of laurocapram and 8g of propylene glycol under continuous stirring at 150 revolutions per minute, and continuously stirring for 25 minutes to obtain a medicine carrier; then adding 350g of compound Chinese medicinal extract No. 3, stirring well, and continuing for 10 minutes at 45 deg.C at 4000 rpm with a high-speed disperser to obtain 1442g of pharmaceutical composition.
The pharmaceutical composition is prepared into solid round tablets with the diameter of 20mm and the weight of 1.2g by a production device which is independently designed and assembled, and 1090 tablets are prepared.
Example 4
Heating 1000g of pungent litse fruit oil at 70 ℃ for melting, sequentially adding 24g of polyglycerol ester-2-oleate, 16g of isostearic acid glyceride, 12g of sorbitan fatty acid ester, 4g of dipotassium glycyrrhizinate, 16g of laurocapram and 8g of propylene glycol under the condition of continuously stirring at 200 revolutions per minute, and continuously stirring for 20 minutes to obtain a medicine carrier; then 250g of compound traditional Chinese medicine extract No. 4 is added and stirred evenly, and then a high-speed disperser is used for keeping at 50 ℃ at 3500 rpm for 20 minutes, thus obtaining 1330g of the pharmaceutical composition.
The pharmaceutical composition is prepared into solid round tablets with the diameter of 20mm and the weight of 1.0g by using a production device which is independently designed and assembled, and 1227 tablets are prepared.
Test examples
Solid circular tablets prepared from the pharmaceutical compositions obtained in examples 1 to 4 were examined for:
1. melting point: which represents the temperature at which the pharmaceutical composition transitions from the solid state to the molten state, as shown in figure 2.
2. Melting time limit: which indicates the time required for the pharmaceutical composition to reach a molten state at 37 c when it is in a solid state, as shown in fig. 3.
Claims (10)
1. The preparation method of the drug carrier based on acupoint transdermal drug delivery is characterized by comprising the following steps:
at least one carrier matrix selected from coconut oil ester, litsea cubeba oil ester, palmitate, cacao butter, coumarate and polyethylene glycol 200, at least one amphiphilic substance selected from sorbitan fatty acid ester, glyceryl monooleate, glyceryl dioleate, glyceryl distearate, polyglycerol ester-2-oleate and glyceryl isostearate, and at least one beneficial additive selected from laurocapram, glycyrrhizic acid and its salts, glycyrrhetinic acid ester, glycerol, propylene glycol and plant aromatic oil.
2. A method of manufacture as claimed in claim 1, wherein the carrier matrix and the amphiphilic substance and the benefit agent are combined under suitable conditions to form a liquid in a homogeneous state, the amphiphilic substance and the benefit agent being present in a ratio of 1-10: 1-10 parts by weight per 100 parts by weight of the carrier matrix.
3. The production method according to claim 1 or 2, wherein the formation method of the homogeneous liquid includes: mixing at 40-90 deg.C for 5-60 min.
4. A pharmaceutical carrier prepared according to the process of any one of claims 1 to 3.
5. A method for preparing an acupoint-based transdermal pharmaceutical composition, wherein a drug is fused with the drug carrier of claim 4 to form a homogeneous liquid melt; the loading amount of the drug carrier is 0.1-0.4 weight part per weight part of the drug carrier.
6. The method of preparing a pharmaceutical composition according to claim 5, wherein the medicament comprises: the extract of single Chinese medicine, the extract of compound Chinese medicine and the plant aromatic oil or the two of them are compatible.
7. The preparation method of the pharmaceutical composition according to claim 5, wherein the extraction method of the traditional Chinese medicine extract according to claim 6 is not limited to the following extraction methods: extracting with water or ethanol (or mixed solvent of water and ethanol) at room temperature or under heating and refluxing, or with the aid of ultrasonic wave or microwave, or purifying with macroporous adsorbent resin, or extracting with supercritical extraction technology.
8. The method of claim 5, wherein the drug and the drug carrier are fused together to form a homogeneous liquid melt.
9. The pharmaceutical composition prepared by the preparation method according to any one of claims 5 to 8, and having the property of interconversion between solid and liquid at a temperature point between 34 and 37 ℃, and having uniform and fine characteristics when in liquid state, is called "liquid melt".
10. The pharmaceutical composition of claim 9, in a range of uses and methods of use based on acupoint transdermal administration use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010210373.7A CN111481528A (en) | 2020-03-23 | 2020-03-23 | Medicine carrier and medicine composition based on acupoint transdermal administration, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010210373.7A CN111481528A (en) | 2020-03-23 | 2020-03-23 | Medicine carrier and medicine composition based on acupoint transdermal administration, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111481528A true CN111481528A (en) | 2020-08-04 |
Family
ID=71789487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010210373.7A Pending CN111481528A (en) | 2020-03-23 | 2020-03-23 | Medicine carrier and medicine composition based on acupoint transdermal administration, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111481528A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069692A (en) * | 2006-05-08 | 2007-11-14 | 范敏华 | Medicine preparation containing centella triterpenic genine and preparing method thereof |
| CN101143127A (en) * | 2007-10-25 | 2008-03-19 | 复旦大学 | Phentolamine external-applied preparation and its preparation method |
| CN101903019A (en) * | 2007-12-27 | 2010-12-01 | 花王株式会社 | Sheet preparation to be applied to the human body |
| CN102462723A (en) * | 2010-11-15 | 2012-05-23 | 复旦大学 | Tripterygium glycoside-containing micro-emulsified gel transdermal preparation and preparation method thereof |
| CN103442678A (en) * | 2010-10-04 | 2013-12-11 | 卡普龙股份有限公司 | Cosmetic skin care compositions |
| CN109464379A (en) * | 2018-12-27 | 2019-03-15 | 沈阳亿欣源生物科技有限公司 | A kind of suppository containing heparan composition |
| CN110464702A (en) * | 2018-05-09 | 2019-11-19 | 上海键合医药科技有限公司 | A kind of ointment and preparation method thereof of gram of vertical boron sieve |
-
2020
- 2020-03-23 CN CN202010210373.7A patent/CN111481528A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069692A (en) * | 2006-05-08 | 2007-11-14 | 范敏华 | Medicine preparation containing centella triterpenic genine and preparing method thereof |
| CN101143127A (en) * | 2007-10-25 | 2008-03-19 | 复旦大学 | Phentolamine external-applied preparation and its preparation method |
| CN101903019A (en) * | 2007-12-27 | 2010-12-01 | 花王株式会社 | Sheet preparation to be applied to the human body |
| CN103442678A (en) * | 2010-10-04 | 2013-12-11 | 卡普龙股份有限公司 | Cosmetic skin care compositions |
| CN102462723A (en) * | 2010-11-15 | 2012-05-23 | 复旦大学 | Tripterygium glycoside-containing micro-emulsified gel transdermal preparation and preparation method thereof |
| CN110464702A (en) * | 2018-05-09 | 2019-11-19 | 上海键合医药科技有限公司 | A kind of ointment and preparation method thereof of gram of vertical boron sieve |
| CN109464379A (en) * | 2018-12-27 | 2019-03-15 | 沈阳亿欣源生物科技有限公司 | A kind of suppository containing heparan composition |
Non-Patent Citations (1)
| Title |
|---|
| 林伟萍等: "《脐部给药的多塞平栓研制及应用》", 《中国现代应用药学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104274578B (en) | A kind of Chinese medicine composition with inhibiting bacteria and diminishing inflammation effect and preparation method thereof | |
| CN102100825B (en) | Chinese medicine composition for treating pains and preparation method thereof | |
| CN111481528A (en) | Medicine carrier and medicine composition based on acupoint transdermal administration, and preparation method and application thereof | |
| CN105434738A (en) | Traditional Chinese medicine composition for treating ADHD (Attention Deficit Hyperactivity Disorder) and preparation method thereof | |
| CN1679697A (en) | Chinese medicine preparation for treating cardio vascular disease and containing notoginseng, pericarpium trichosanthis and leech, for treating cardio-cerebral blood vessel diseases and its preparing | |
| CN109288904A (en) | The Chinese medicine composition and its preparation method and application of prevention or treatment arrhythmia cordis | |
| CN104958429A (en) | Traditional Chinese medicinal composition for treating geriatric fracture and preparation method thereof | |
| CN104997858B (en) | A kind of Chinese medicine composition and preparation method thereof for treating the periarthritis of shoulderjoint | |
| CN109820884B (en) | Composite aucklandia root oil self-emulsifying soft capsule with stomach invigorating function and preparation method and application thereof | |
| KR20220138397A (en) | Chinese medicine composition and its method and application | |
| CN105943595A (en) | Medicine for treating chemotherapy induced hand-foot syndromes and targeted therapy induced hand-foot skin reactions and preparation method thereof | |
| CN101618063A (en) | Medicine for treating prostate gland diseases and preparation method thereof | |
| CN107126450B (en) | A Chinese medicinal preparation containing extract and effective substance, and its preparation method and application | |
| CN102309724B (en) | Pharmaceutical composition for treating breast diseases and preparation method thereof | |
| CN104623499A (en) | Traditional Chinese medicine preparation for assisting acupuncture treatment of diabetic gastroparesis and preparation method and applications thereof | |
| CN103861078A (en) | Snake-scorpion pain-relieving and wind-dispelling liquor and preparation method thereof | |
| CN102895583A (en) | Preparation technology and production method for integrated new formulation of ginseng, poria, and atractylodes macrocephala powder | |
| CN102100769A (en) | Preparation technique for ephedra and bighead atractylodes rhizome decoction in novel formed formulation and production method thereof | |
| CN100379449C (en) | Compositions of SOD and vetetative medicine or its extractives, and its prepn. method | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN1539493A (en) | Combination of Chinese traditional medicine for curing disease of respiratory system and preparing method | |
| CN102743480B (en) | Traditional Chinese medicine preparation for treating hepatitis and preparation method thereof | |
| CN107469014A (en) | A kind of pharmaceutical composition for treating female mammary gland proliferation disease and preparation method thereof | |
| CN102284024A (en) | Preparation technology of integrated novel Weijing decoction dosage form | |
| CN106074691A (en) | The Folium Pini compound recipe unguentum of a kind of promoting blood circulation, removing blood stasis and relieving pain and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |